Differential regulation of elevated renal angiotensin II in chronic renal ischemia.
The present study was undertaken to clarify the role of intrarenal angiotensin (Ang) II and its generating pathways in clipped and nonclipped kidneys of 4-week unilateral renal artery stenosis in anesthetized dogs. After 4 weeks, renal plasma flow (RPF) decreased in clipped and nonclipped kidneys (baseline, 59+/-3; clipped, 16+/-1; nonclipped, 44+/-2 mL/min; P<0.01, n=22). Renal Ang I levels increased only in clipped, whereas intrarenal Ang II contents were elevated in both clipped (from 0.7+/-0.1 to 2.0+/-0.2 pg/mg tissue) and nonclipped kidneys (from 0.6+/-0.1 to 2.5+/-0.3 pg/mg tissue). Intrarenal ACE activity was increased in nonclipped kidneys but was unaltered in clipped kidneys. An angiotensin receptor antagonist (olmesartan medoxomil) given into the renal artery markedly restored RPF, and dilated both afferent and efferent arterioles (using intravital videomicroscopy). Furthermore, in clipped kidneys, the elevated Ang II was suppressed by a chymase inhibitor, chymostatin (from 2.1+/-0.6 to 0.8+/-0.1 pg/mg tissue; P<0.05), but not by cilazaprilat. In nonclipped kidneys, in contrast, cilazaprilat, but not chymostatin, potently inhibited the intrarenal Ang II generation (from 2.4+/-0.3 to 1.5+/-0.2 pg/mg tissue; P<0.05). Finally, [Pro11-D-Ala12]Ang I (an inactive precursor that yields Ang II by chymase but not by ACE; 1 to 50 nmol/kg) markedly elevated intrarenal Ang II in clipped, but not in nonclipped, kidneys. In conclusion, renal Ang II contents were elevated in both clipped and nonclipped kidneys, which contributed to the altered renal hemodynamics and microvascular tone. Furthermore, the mechanisms for intrarenal Ang II generation differ, and chymase activity is enhanced in clipped kidneys, whereas ACE-mediated Ang II generation is possibly responsible for elevated Ang II contents in nonclipped kidneys.
Tokuyama
Hirobumi
H
Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan.
Hayashi
Koichi
K
Matsuda
Hiroto
H
Kubota
Eiji
E
Honda
Masanori
M
Okubo
Ken
K
Takamatsu
Ichiro
I
Tatematsu
Satoru
S
Ozawa
Yuri
Y
Wakino
Shu
S
Saruta
Takao
T
D000803:Angiotensin I / Q000378:metabolism; D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D002908:Chronic Disease; D053818:Chymases; D017315:Cilazapril / Q000031:analogs & derivatives* / Q000494:pharmacology; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D006977:Hypertension, Renal / Q000378:metabolism / Q000503:physiopathology; D007093:Imidazoles / Q000494:pharmacology; D007511:Ischemia / Q000378:metabolism* / Q000503:physiopathology; D007668:Kidney / Q000098:blood supply / Q000378:metabolism*; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D000068557:Olmesartan Medoxomil; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D012079:Renal Circulation / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000502:physiology; D012697:Serine Endopeptidases / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology
D007093:Imidazoles; D009842:Oligopeptides; D013777:Tetrazoles; D000804:Angiotensin II; D017315:Cilazapril; D000068557:Olmesartan Medoxomil; D000803:Angiotensin I; C002101:chymostatin; D007703:Peptidyl-Dipeptidase A; D012697:Serine Endopeptidases; D053818:Chymases; C045980:cilazaprilat